Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.52 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGAV | P06756 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14540295 | 1.00 | ERCC1 (0.52) | ERCC1ERCC4ACEMMEITGB3 | |
| SCHEMBL9829520 | 0.89 | TRPV1 (0.53) | ERCC1ERCC4TRPV1ALDH1A1 | |
| SCHEMBL8767346 | 0.87 | NAAA (0.55) | ERCC1ERCC4TRPV1ALDH1A1 | |
| SCHEMBL11471099 | 0.85 | GLI1 (0.59) | ERCC1ERCC4TRPV1ALDH1A1 | |
| SCHEMBL28658959 | 0.84 | GPR88 (0.56) | ERCC1ERCC4TRPV1ALDH1A1 | |
| SCHEMBL19245448 | 0.84 | GPR88 (0.56) | ERCC1ERCC4TRPV1ALDH1A1 | |
| SCHEMBL24045921 | 0.83 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL6137585 | 0.82 | MME (0.62) | ERCC1ERCC4ACEMMEITGB3 | |
| SCHEMBL9832121 | 0.82 | CNR1 (0.69) | ACEMMEALDH1A1 | |
| SCHEMBL5842738 | 0.82 | TRPV1 (0.56) | ERCC1ERCC4TRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | ERCC1 1510/4885ERCC4 1427/4885ACE 1561/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | ERCC1 993/4885ERCC4 1174/4885ACE 475/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | ERCC1 1489/4885ERCC4 1561/4885ACE 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.